Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Haanen

Showing results (1-10 of 86) with videos related to

Pageof 9
Sort By:
Trends in Cancer|May 29, 2025
Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?John B Haanen
Immuno-Oncology Technology|June 27, 2022
Getting visible with exciting IO tech!John B Haanen
Immuno-Oncology Technology|June 27, 2022
IOTECH: Present, future and the future of the futureJohn B Haanen
Immuno-Oncology Technology|June 27, 2022
The promise of IO and IOTECHJohn B Haanen
The Lancet. Haematology|December 12, 2018
Characterisation of rare haematological immune-related toxicitiesJohn B Haanen, Solange Peters
Med (New York, N.Y.)|April 13, 2024
Melanoma neoantigen vaccines: Are we getting more personal now?Sofiya Latifyan, John B Haanen
Cell Reports. Medicine|June 22, 2022
TIL classified to memory state are correlated with response to immune checkpoint blockadeInge Jedema, John B Haanen
Cell|December 15, 2018
NKG2A, a New Kid on the Immune Checkpoint BlockJohn B Haanen, Vincenzo Cerundolo
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|February 29, 2020
Cancer management in the era of immunotherapy: much more than meets the eyeEgesta Lopci, John B Haanen
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|May 19, 2020
Prognostic and predictive role of the tumor immune landscapeJohn B Haanen, Christian U Blank
Pageof 9

Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
Trends in Cancer|May 29, 2025
Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?John B Haanen
Immuno-Oncology Technology|June 27, 2022
Getting visible with exciting IO tech!John B Haanen
Immuno-Oncology Technology|June 27, 2022
IOTECH: Present, future and the future of the futureJohn B Haanen
Immuno-Oncology Technology|June 27, 2022
The promise of IO and IOTECHJohn B Haanen
The Lancet. Haematology|December 12, 2018
Characterisation of rare haematological immune-related toxicitiesJohn B Haanen, Solange Peters
Med (New York, N.Y.)|April 13, 2024
Melanoma neoantigen vaccines: Are we getting more personal now?Sofiya Latifyan, John B Haanen
Cell Reports. Medicine|June 22, 2022
TIL classified to memory state are correlated with response to immune checkpoint blockadeInge Jedema, John B Haanen
Cell|December 15, 2018
NKG2A, a New Kid on the Immune Checkpoint BlockJohn B Haanen, Vincenzo Cerundolo
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|February 29, 2020
Cancer management in the era of immunotherapy: much more than meets the eyeEgesta Lopci, John B Haanen
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|May 19, 2020
Prognostic and predictive role of the tumor immune landscapeJohn B Haanen, Christian U Blank
Pageof 9